Pancreatic Cancer Research

ResearcherHyogo Ion Beam Medical CenterActive in the last 2 years

Kazuki Terashima

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0009-0003-1198-5554; OpenAlex author ID A5050491832. Sources: OpenAlex.

Their work

Papers
7 (first author 4, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
15
Papers, trials and grants by year

2012: 1 paper · 2013: none · 2014: 1 paper · 2015: none · 2016: 1 paper · 2017: none · 2018: none · 2019: 1 paper · 2020: none · 2021: none · 2022: 1 paper · 2023: 1 paper · 2024: none · 2025: none · 2026: 1 paper

Papers 7

  1. Proton Radiotherapy with Induction Chemotherapy for Locally Advanced Pancreatic Cancer: A Retrospective Analysis of Treatment Strategy and Outcomes. Co-author DOI 10.1016/j.clon.2026.104204↗
  2. Proton radiotherapy as a treatment strategy to increase survival in locally advanced pancreatic cancer in the body and tail: a retrospective study. First author DOI 10.1186/s13014-023-02301-9↗
  3. Factors associated with long-term survival in gemcitabine-concurrent proton radiotherapy for non-metastatic locally advanced pancreatic cancer: a single-center… First author DOI 10.1186/s13014-022-02001-w↗
  4. Proton Radiotherapy for Isolated Local Recurrence of Primary Resected Pancreatic Ductal Adenocarcinoma. First author DOI 10.1245/s10434-019-07471-z↗
  5. The Usefulness of Using Fiducial Marker in Proton Therapy for Locally Advanced Pancreatic Cancer. Co-author DOI 10.6009/jjrt.2016_jsrt_72.11.1074↗
  6. Upper gastrointestinal complications associated with gemcitabine-concurrent proton radiotherapy for inoperable pancreatic cancer. First author DOI 10.1007/s00535-013-0857-3↗
  7. A phase I/II study of gemcitabine-concurrent proton radiotherapy for locally advanced pancreatic cancer without distant metastasis. Co-author DOI 10.1016/j.radonc.2011.12.029↗

Closest collaborators

The 15 strongest of 15 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Tomoaki Okimoto · 4 shared papers, 2019–2026 · strength 0.64
  2. Hirochika Toyama · 4 shared papers, 2019–2026 · strength 0.64
  3. Takumi Fukumoto · 4 shared papers, 2019–2026 · strength 0.64
  4. Katsuya Ami · 2 shared papers, 2023–2026 · strength 0.41
  5. Yoshihide Nanno · 2 shared papers, 2022–2023 · strength 0.30
  6. Jun Ishida · 1 shared paper, 2023 · strength 0.16
  7. Yuta Ogura · 1 shared paper, 2022 · strength 0.14
  8. Takuya Mizumoto · 1 shared paper, 2019 · strength 0.09
  9. Ryoji Ida · 1 shared paper, 2016 · strength 0.07
  10. Masakazu Shimizu · 1 shared paper, 2016 · strength 0.07
  11. Kento Takatori · 2 shared papers, 2012–2014 · strength 0.07
  12. Nobukazu Fuwa · 1 shared paper, 2014 · strength 0.04
  13. Masao Murakami · 1 shared paper, 2012 · strength 0.03
  14. Ryohei Sasaki · 1 shared paper, 2012 · strength 0.03
  15. Yonson Ku · 1 shared paper, 2012 · strength 0.03

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.